Introduction to Oceanic Stroke Translating Landmark Results Into Clinical Practice
Welcome to our comprehensive guide on Oceanic Stroke Translating Landmark Results Into Clinical Practice. Join us for an engaging and timely webinar exploring the groundbreaking
Oceanic Stroke Translating Landmark Results Into Clinical Practice Comprehensive Overview
Mike Sharma, MD, MSc, FRCPC, McMaster University, Hamilton, Canada, shares the primary Cheryl Bushnell, MD, MHS, FAHA, Chair, Asundexian, an investigational oral Factor XIa (FXIa) inhibitor
Episode 1 of the World
Summary & Highlights for Oceanic Stroke Translating Landmark Results Into Clinical Practice
- Mike Sharma, MD, MSc, FRCPC, McMaster University, Hamilton, Canada, discusses the ongoing
- Simona Sacco, MD, University of L'Aquila, L'Aquila, Italy, shares her perspective on
- Ashkan Shoamanesh, MD, McMaster University, Population Health Research Institute, Hamilton, Canada, discusses a ...
- Showed Asundexian was associated with a reduced occurrence of ischemic
- Mike Sharma, MD, MSc, FRCPC, McMaster University, Hamilton, Canada, discusses two analyses of the
In summary, understanding Oceanic Stroke Translating Landmark Results Into Clinical Practice gives us a better perspective.